We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SP Platform's 88% Procedure Growth: The Next Frontier for ISRG?
Read MoreHide Full Article
Key Takeaways
ISRG's SP procedures surged 88% YoY, with Korea driving 112% growth in Q2 2025.
ISRG broadened SP use from urology into colorectal, thoracic, and transanal cases.
ISRG saw SP utilization rise 30% despite modest 23 system placements in Q2.
Intuitive Surgical’s (ISRG - Free Report) second-quarter 2025 results highlighted an impressive 88% year-over-year surge in single-port (SP) procedures, underscoring the platform’s accelerating momentum within the company’s broader portfolio. While da Vinci multiport systems remain the backbone of Intuitive’s installed base, SP’s performance — particularly outside the United States —suggests it may be emerging as the next meaningful growth driver along with Ion platform.
Korea stood out with a 112% procedure increase, fueled by highly efficient, high-utilization programs that continue to expand across multiple surgical specialties. Europe and Japan are progressing steadily, albeit at earlier stages of adoption. This global spread signals not just geographical diversification but also rising confidence among surgeons in SP’s clinical utility.
A key factor in SP’s expanding adoption is its broadening clinical footprint. Initially centered on urology, the platform is now gaining traction in colorectal, thoracic and transanal procedures. The rollout of the SP stapler — viewed as a critical enabler for complex colorectal and thoracic surgeries — further strengthens its potential for case volume expansion.
Financially, SP placements were modest at 23 systems in the second quarter, yet utilization rose 30%, indicating that installed systems are seeing higher throughput. Strong uptake in Korea and increasing European and Japanese usage point to SP’s ability to drive procedure growth even without large-scale system placements.
The question for investors is whether SP can replicate the multiport da Vinci’s trajectory and evolve into a core volume engine for Intuitive Surgical. With rising adoption beyond urology and early evidence of efficiency gains, SP appears well-positioned to be more than just an adjunct platform. Its sustained growth could mark the next frontier in Intuitive Surgical’s long-term expansion story.
Competitive Snapshot
PROCEPT BioRobotics (PRCT - Free Report) markets the AquaBeam Robotic System, which performs image-guided, heat-free waterjet aquablation for benign prostatic hyperplasia (BPH). PROCEPT BioRobotics’ AquaBeam delivers highly precise, automated tissue removal under ultrasound guidance, appealing to urology practices and overlapping with Intuitive Surgical’s early SP urology use cases. PROCEPT BioRobotics’ targeted platform may thus rival SP by capturing procedural volume in urology with a technology-specific advantage. Last year, PRCT launched its next-generation, AI-powered platform for Aquablation therapy, HYDROS Robotic System, for treating BPH.
Simultaneously, Globus Medical (GMED - Free Report) showcased its ExcelsiusFlex robotic navigation system for Total Knee Arthroplasty. Its system offers both CT-based and imageless registration options, providing surgeons with ergonomic control and procedural flexibility. Globus Medical’s ExcelsiusFlex is designed to enhance surgical precision and accommodate diverse patient needs and surgeon preferences.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 9.2% in the year-to-date period compared with the industry’s decline of 8.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 53.65, above the industry average. But, it is still lower than its five-year median of 72.05. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies an 11.3% rise from the year-ago period’s level.
Image: Shutterstock
SP Platform's 88% Procedure Growth: The Next Frontier for ISRG?
Key Takeaways
Intuitive Surgical’s (ISRG - Free Report) second-quarter 2025 results highlighted an impressive 88% year-over-year surge in single-port (SP) procedures, underscoring the platform’s accelerating momentum within the company’s broader portfolio. While da Vinci multiport systems remain the backbone of Intuitive’s installed base, SP’s performance — particularly outside the United States —suggests it may be emerging as the next meaningful growth driver along with Ion platform.
Korea stood out with a 112% procedure increase, fueled by highly efficient, high-utilization programs that continue to expand across multiple surgical specialties. Europe and Japan are progressing steadily, albeit at earlier stages of adoption. This global spread signals not just geographical diversification but also rising confidence among surgeons in SP’s clinical utility.
A key factor in SP’s expanding adoption is its broadening clinical footprint. Initially centered on urology, the platform is now gaining traction in colorectal, thoracic and transanal procedures. The rollout of the SP stapler — viewed as a critical enabler for complex colorectal and thoracic surgeries — further strengthens its potential for case volume expansion.
Financially, SP placements were modest at 23 systems in the second quarter, yet utilization rose 30%, indicating that installed systems are seeing higher throughput. Strong uptake in Korea and increasing European and Japanese usage point to SP’s ability to drive procedure growth even without large-scale system placements.
The question for investors is whether SP can replicate the multiport da Vinci’s trajectory and evolve into a core volume engine for Intuitive Surgical. With rising adoption beyond urology and early evidence of efficiency gains, SP appears well-positioned to be more than just an adjunct platform. Its sustained growth could mark the next frontier in Intuitive Surgical’s long-term expansion story.
Competitive Snapshot
PROCEPT BioRobotics (PRCT - Free Report) markets the AquaBeam Robotic System, which performs image-guided, heat-free waterjet aquablation for benign prostatic hyperplasia (BPH). PROCEPT BioRobotics’ AquaBeam delivers highly precise, automated tissue removal under ultrasound guidance, appealing to urology practices and overlapping with Intuitive Surgical’s early SP urology use cases. PROCEPT BioRobotics’ targeted platform may thus rival SP by capturing procedural volume in urology with a technology-specific advantage. Last year, PRCT launched its next-generation, AI-powered platform for Aquablation therapy, HYDROS Robotic System, for treating BPH.
Simultaneously, Globus Medical (GMED - Free Report) showcased its ExcelsiusFlex robotic navigation system for Total Knee Arthroplasty. Its system offers both CT-based and imageless registration options, providing surgeons with ergonomic control and procedural flexibility. Globus Medical’s ExcelsiusFlex is designed to enhance surgical precision and accommodate diverse patient needs and surgeon preferences.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 9.2% in the year-to-date period compared with the industry’s decline of 8.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 53.65, above the industry average. But, it is still lower than its five-year median of 72.05. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies an 11.3% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.